Pfizer Operating Expenses 2012-2026 | PFE
Pfizer annual/quarterly operating expenses history and growth rate from 2012 to 2026. Operating expenses can be defined as the sum of all operating expenses for the given industry.
- Pfizer operating expenses for the quarter ending March 31, 2026 were $10.419B, a 4.43% increase year-over-year.
- Pfizer operating expenses for the twelve months ending March 31, 2026 were $48.777B, a 3.25% decline year-over-year.
- Pfizer annual operating expenses for 2025 were $48.335B, a 5.63% decline from 2024.
- Pfizer annual operating expenses for 2024 were $51.216B, a 12.11% decline from 2023.
- Pfizer annual operating expenses for 2023 were $58.274B, a 10.88% decline from 2022.
|
Pfizer Annual Operating Expenses (Millions of US $) |
|
|---|---|
| 2025 | $48,335 |
| 2024 | $51,216 |
| 2023 | $58,274 |
| 2022 | $65,386 |
| 2021 | $61,855 |
| 2020 | $33,401 |
| 2019 | $34,195 |
| 2018 | $35,153 |
| 2017 | $38,824 |
| 2016 | $40,679 |
| 2015 | $37,027 |
| 2014 | $36,356 |
| 2013 | $36,400 |
| 2012 | $39,393 |
| 2011 | $47,068 |
|
Pfizer Quarterly Operating Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $10,419 |
| 2025-12-31 | $14,685 |
| 2025-09-30 | $12,803 |
| 2025-06-30 | $10,870 |
| 2025-03-31 | $9,977 |
| 2024-12-31 | $15,416 |
| 2024-09-30 | $12,743 |
| 2024-06-30 | $12,280 |
| 2024-03-31 | $10,777 |
| 2023-12-31 | $18,857 |
| 2023-09-30 | $16,662 |
| 2023-06-30 | $10,813 |
| 2023-03-31 | $11,942 |
| 2022-12-31 | $19,908 |
| 2022-09-30 | $13,695 |
| 2022-06-30 | $15,523 |
| 2022-03-31 | $16,260 |
| 2021-12-31 | $20,847 |
| 2021-09-30 | $17,888 |
| 2021-06-30 | $13,293 |
| 2021-03-31 | $9,827 |
| 2020-12-31 | $10,724 |
| 2020-09-30 | $7,829 |
| 2020-06-30 | $7,792 |
| 2020-03-31 | $7,056 |
| 2019-12-31 | $6,771 |
| 2019-09-30 | $9,722 |
| 2019-06-30 | $8,998 |
| 2019-03-31 | $8,704 |
| 2018-12-31 | $7,172 |
| 2018-09-30 | $9,534 |
| 2018-06-30 | $9,490 |
| 2018-03-31 | $8,957 |
| 2017-12-31 | $11,396 |
| 2017-09-30 | $9,504 |
| 2017-06-30 | $9,155 |
| 2017-03-31 | $8,769 |
| 2016-12-31 | $11,871 |
| 2016-09-30 | $10,024 |
| 2016-06-30 | $9,670 |
| 2016-03-31 | $9,114 |
| 2015-12-31 | $12,213 |
| 2015-09-30 | $8,729 |
| 2015-06-30 | $8,258 |
| 2015-03-31 | $7,827 |
| 2014-12-31 | $10,971 |
| 2014-09-30 | $8,679 |
| 2014-06-30 | $8,823 |
| 2014-03-31 | $7,883 |
| 2013-12-31 | $10,515 |
| 2013-09-30 | $8,659 |
| 2013-06-30 | $8,686 |
| 2013-03-31 | $8,540 |
| 2012-12-31 | $10,291 |
| 2012-09-30 | $9,210 |
| 2012-06-30 | $9,100 |
| 2012-03-31 | $10,792 |
| 2011-12-31 | $9,526 |
| 2011-09-30 | $12,521 |
| 2011-06-30 | $12,464 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |